<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114189">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01757067</url>
  </required_header>
  <id_info>
    <org_study_id>53625 Evac-HF</org_study_id>
    <nct_id>NCT01757067</nct_id>
  </id_info>
  <brief_title>Early Elimination of Premature Ventricular Contractions in Heart Failure</brief_title>
  <acronym>EVAC-HF</acronym>
  <official_title>EVAC-HF is a Prospective, Multi-center, Randomized Study to Compare the Effects on LV Systolic Function Following Radiofrequency Catheter Ablation of Frequent Premature Ventricular Contraction With Optimized Medical Therapy Alone.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Premature ventricular contractions (PVC) are a very common irregular heart beat
      (arrhythmias) even in patients without heart disease. Frequent PVCs are thought to occur in
      about 1-4% of the general population. Many patients with PVCs complain about skipping of
      their heart (palpitations), shortness of breath and feeling tired. In some patients PVCs may
      also result in weakening of the heart muscle (heart failure), which might be reversible with
      suppression of the PVCs.

      A common way to get rid of PVCs is an ablation procedure during which a small area of heart
      muscle that creates the PVCs is cauterized, so that it can no longer cause PVCs. This has
      been performed for many years and is an overall safe and effective procedure to eliminate
      PVCs. In the ablation, a catheter with an electrode at its tip is guided with moving X-rays
      (fluoroscopy) displayed on a video screen to the exact site inside the heart where cells
      give off the electrical signals that stimulate the abnormal heart rhythm. Radiofrequency
      energy (similar to microwave heat) is transmitted from the catheter tip to the area. This
      destroys carefully selected heart muscle cells in a very small area (about 1/5 of an inch)
      and can stop the area from creating the extra impulses that cause the extra heartbeats.
      Additionally, some medications have the ability to suppress PVCs (antiarrhythmic
      medications). PVC ablation and antiarrhythmic medications have both been used to treat
      patients with PVC's and a reduced heart function. The heart function is referred to as
      ejection fraction (measured by cardiac ultrasound (echocardiogram). In this study it will be
      required the ejection fraction will be less than less than or equal to 45% (with 55% or more
      being normal).

      If  enrolled in the study there is a 50/50 chance (like a coin toss and referred to as
      randomization) that the patient will either continue on the best currently available medical
      treatment for a weak heart muscle (as determined by the doctor) or will undergo a PVC
      catheter ablation (with a possible second ablation or antiarrhythmic medication, if the
      first ablation was not a success).

      All patients in the study will continue to take the best possible medications for the heart
      muscle weakness. If the patient is randomized to not undergo the ablation they will be
      monitored and at the end of 6 months of participation may choose to have the PVC ablation.
      If a deterioration may occur patients in the control group can have an ablation earlier.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>change of left ventricular ejection fraction measured with Simpson's rule expressed in percent from pre to post intervention</measure>
    <time_frame>0 and 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Ejection fraction by Echocardiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of echocardiographic Parameters</measure>
    <time_frame>0 and 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Left Ventricular end-systolic volume index (LVESVI) Left Ventricular end-systolic dimension Left Ventricular end-diastolic volume Left Ventricular end-diastolic dimension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum biomarker level</measure>
    <time_frame>0 and 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>BNP, hs-Troponin, galectin-3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Heart Failure Symptoms</measure>
    <time_frame>0 and 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assessed by heart failure questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Premature Ventricular Contractions</condition>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>ablation procedure vs medical therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PVC ablation vs medical therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Compare 2 arms for safety, symptoms</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Compare control of PVC's between 2 groups.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PVC ablation</intervention_name>
    <description>This will compare symptoms, safety between ablation procedure vs medical therapy. Biosense Catheter used is not indicated specifically for PVC ablations and will be evaluated</description>
    <arm_group_label>ablation procedure vs medical therapy</arm_group_label>
    <other_name>Surround Flow ablation catheters- Biosense Webster</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with reduced ejection fraction (EF â‰¤45%) demonstrated by transthoracic
             echocardiogram and deemed to be non-ischemic by nuclear stress test or cardiac
             catheterization.

          -  Patients with &gt;20% PVCs on 24 hour holter-recording

          -  Patient is 18 years of age or older

          -  Optimized medical therapy on stable therapy for minimum 3 months with no changes in
             beta-blocker, ACE-I/ARB, digoxin doses (varying diuretic doses permitted).

        Exclusion Criteria:

          -  Patients who are under the age of 18 years of age

          -  Patients with &gt;2 dominant PVC morphologies

          -  Patients with cardiac surgery in previous 3 months or scheduled for following 6
             months

          -  Patients who were implanted with a biventricular device during the last three months
             or single/dual chamber device (with ventricular pacing &gt;10%) during the last three
             months

          -  Significant symptoms associated with PVCs that would make favor immediate ablation

          -  Intracardiac mural thrombus or  myxoma

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timm Dickfeld, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Timm Dickfeld, MD, PhD</last_name>
    <phone>410-328-7801</phone>
    <email>tdickfel@medicine.umaryland.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dawn Ament, RN</last_name>
    <phone>410-328-7801</phone>
    <email>dament1@medicine.umaryland.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kalyanam Shivkumar, MD</last_name>
      <phone>310-206-6433</phone>
      <email>kshivkumar@mednet.edu</email>
    </contact>
    <investigator>
      <last_name>Kalyanam Shivkumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loyola University Health System</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Wilber, MD</last_name>
      <email>dwilber@lumc.edu</email>
    </contact>
    <investigator>
      <last_name>David Wilber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Timm Dickfeld, PhD</last_name>
      <phone>410-328-7801</phone>
      <email>tdickfel@medicine.umaryland.edu</email>
    </contact>
    <contact_backup>
      <last_name>Dawn Ament, RN</last_name>
      <phone>410-328-7801</phone>
      <email>dament1@medicine.umaryland.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Timm Dickfeld, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roy John, MD</last_name>
      <phone>857-307-1946</phone>
      <email>rjohn2@partners.org</email>
    </contact>
    <contact_backup>
      <last_name>Christine Pelligrini</last_name>
      <email>cpelligrini@partners.org</email>
    </contact_backup>
    <investigator>
      <last_name>Roy John, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-311</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frank Bogun, MD</last_name>
      <phone>734-936-6858</phone>
      <email>fbogun@med.umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jacqueline Fortino</last_name>
      <phone>734-936-6858</phone>
      <email>jfortino@med.umch.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Frank Bogun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1252</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emile Daoud, MD</last_name>
      <email>Emile.Daoud@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Julie Ryan</last_name>
      <email>Julie.Ryan@osumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Emile Daoud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francis Marchlinski, MD</last_name>
      <phone>215-662-6005</phone>
      <email>Francis.Marchlinski@uphs.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Roseanne Clayton</last_name>
      <phone>215-662-6005</phone>
      <email>Roseanne.Clayton@uphs.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Francis Marchlinski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Quebec</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Francois Sarrazin, MD</last_name>
      <phone>418-656-8711</phone>
      <email>jfsarrazin@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Paule Baville</last_name>
      <phone>418-656-8711</phone>
      <email>Paule.Baville@criucpq.ulaval.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Francois Sarrazin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 31, 2012</lastchanged_date>
  <firstreceived_date>December 3, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland</investigator_affiliation>
    <investigator_full_name>Timm-Michael Dickfeld, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>ablations</keyword>
  <keyword>CHF</keyword>
  <keyword>PVC</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Ventricular Premature Complexes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
